logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
S

Shanu Modi

Vita-Salute San Raffaele University

60H指数
417论文数
2.0W被引数
收录论文 136
发表时间
logo
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies根据剂量对曲妥珠单抗德鲁替康的安全性特征进行表征：一项跨越DESTINY研究的合并分析
errONCOLOGIST
IF4.2
err2026-01-01
err0
PREAI
errPark, Yeon Hee; Cortes, Javier; Modi, Shanu; Hurvitz, Sara A.; Bianchini, Giampaolo; Iwata, Hiroji; Shitara, Kohei; Siena, Salvatore; Goto, Yasushi; Ku, Geoffrey Y.; Powell, Charles A.; Swain, Sandra M.; Arunachalam, Meena; Janek, Martin; Cheng, Yingkai; Chu, Changan; Verma, Purnima; Kuptsova-Clarkson, Nataliya; Mathias, Elton; Goodman, Erin; Rugo, Hope S.
err分享
err收藏
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer评估T-DXd治疗后HER2阳性转移性乳腺癌的治疗策略
errBREAST CANCER RESEARCH AND TREATMENT
IF3
err2025-11-27
err0
errOAAI
errZelizer, Sophia; Gallagher, Grace B.; Gonen, Mithat; Dang, Chau; Modi, Shanu; Chandarlapaty, Sarat; Drago, Joshua Z.
err分享
err收藏
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03来自DESTINY-Breast01，DESTINY-Breast02和DESTINY-Breast03的HER2-positive转移性乳腺癌患者对曲妥珠单抗deruxtecan和相关生物标志物的最佳确认反应的汇总分析
errAnnals of Oncology
IF65.4
err2025-11-18
err0
PREAI
errC. Saura; J. Cortés; S. Modi; S.-B. Kim; E. Hamilton; S.A. Hurvitz; I.E. Krop; G. Curigliano; H. Iwata; S.-A. Im; P. Herbolsheimer; M. Karnoub; A. Boran; Y. Kuwahara; A. Egorov; F. André
err分享
err收藏
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial新辅助曲妥珠单抗德鲁替康单药或序贯多西他赛、曲妥珠单抗和帕妥珠单抗治疗高危HER2阳性早期乳腺癌（DESTINY-Breast11）：一项随机、开放标签、多中心、III期临床试验
errAnnals of Oncology
IF65.4
err2025-10-21
err0
errOAAI
errNadia Harbeck; Shanu Modi; Lajos Pusztai; Shinji Ohno; Jiong Wu; Sung-Bae Kim; Atsushi Yoshida; Alessandra Fabi; Xuchen Cao; Rona Joseph; Rubi Li; Bogdan Żurawski; Santiago Escrivá-de-Romaní; Renata Meneguetti; Archara Supavavej; Shin-Cheh Chen; Zhenzhen Liu; Catherine Kelly; Giuseppe Curigliano; William F. Symmans; Mohammad Gufran; Jun Ke; Adam Konpa; Pia Herbolsheimer; Jean-François Boileau
err分享
err收藏
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial曲妥珠单抗德鲁替康在HER2低表达转移性乳腺癌中的应用：DESTINY-Breast04随机三期试验的长期生存分析
errNature Medicine
IF50
err2025-10-08
err0
errOAAI
errShanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
err分享
err收藏
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis曲妥珠单抗德鲁替康再次治疗后1级间质性肺疾病/肺炎的恢复：合并分析
errAnnals of Oncology
IF65.4
err2025-08-05
err0
errOAAI
errH.S. Rugo; E. Tokunaga; H. Iwata; V. Petry; E.F. Smit; Y. Goto; D.-W. Kim; K. Shitara; J.F. Gruden; S. Modi; J. Cortés; I. Krop; P.A. Jänne; Y. Cheng; C. Taitt; F.-C. Cheng; C.A. Powell
err分享
err收藏
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted TherapyHER2靶向治疗期间减少心脏毒性监测的心脏安全性
errJACC: CardioOncology
IF12.8
err2025-06-17
err0
errOAAI
errAnthony F. Yu; Chau T. Dang; Chaya S. Moskowitz; Akriti Mishra Meza; Patricia DeFusco; Eric Oligino; Carol L. Chen; Rachel Sanford; Pamela Drullinsky; Jacqueline Bromberg; Serena Wong; Shanu Modi; Justine Jorgensen; Kevin C. Oeffinger; Richard M. Steingart; Jennifer E. Liu
err分享
err收藏
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study
errBREAST CANCER RESEARCH AND TREATMENT
IF3
err2025-03-01
err0
errOAAI
errModi, Shanu; Zhang, Suyuan; Byng, Danalyn; Hunter, Shannon; Struebing, Alessandria; Xiong, Yan; Dunton, Kyle; Mbanya, Zacharie; Jacot, William
err分享
err收藏
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
errFUTURE ONCOLOGY
IF2.6
err2025-01-09
err0
errOAAI
errModi, Shanu
err分享
err收藏
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
errNATURE REVIEWS CLINICAL ONCOLOGY
IF82.2
err2024-11-06
err0
PREAI
errDrago, Joshua; Modi, Shanu
err分享
err收藏
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
errNPJ BREAST CANCER
IF7.6
err2024-10-28
err0
errOAAI
errChew, S. M.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D.; Modi, S.; Seidman, A. D.; Wen, H.; Brogi, E.; Robson, M.; Dang, C. T.
err分享
err收藏
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
errNPJ BREAST CANCER
IF7.6
err2024-10-18
err1
errOAAI
errMai, Nicholas; dos Anjos, Carlos H.; Razavi, Pedram; Safonov, Anton; Patil, Sujata; Chen, Yuan; Drago, Joshua Z.; Modi, Shanu; Bromberg, Jacqueline F.; Dang, Chau T.; Liu, Dazhi; Norton, Larry; Robson, Mark; Chandarlapaty, Sarat; Jhaveri, Komal
err分享
err收藏
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
errNATURE COMMUNICATIONS
IF15.7
err2024-10-16
err0
errOAAI
errRoychowdhury, Tanaya; McNutt, Seth W.; Pasala, Chiranjeevi; Nguyen, Hieu T.; Thornton, Daniel T.; Sharma, Sahil; Botticelli, Luke; Digwal, Chander S.; Joshi, Suhasini; Yang, Nan; Panchal, Palak; Chakrabarty, Souparna; Bay, Sadik; Markov, Vladimir; Kwong, Charlene; Lisanti, Jeanine; Chung, Sun Young; Ginsberg, Stephen D.; Yan, Pengrong; De Stanchina, Elisa; Corben, Adriana; Modi, Shanu; Alpaugh, Mary L.; Colombo, Giorgio; Erdjument-Bromage, Hediye; Neubert, Thomas A.; Chalkley, Robert J.; Baker, Peter R.; Burlingame, Alma L.; Rodina, Anna; Chiosis, Gabriela; Chu, Feixia
err分享
err收藏
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives (vol 21, pg 185, 2024)
errNATURE REVIEWS CLINICAL ONCOLOGY
IF82.2
err2024-08-02
err0
errOAAI
errMarra, Antonio; Chandarlapaty, Sarat; Modi, Shanu
err分享
err收藏
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study在先前接受过治疗的HER2-low不可切除/转移性乳腺癌的亚洲患者中，曲妥珠单抗deruxtecan与医生选择的治疗: DESTINY-Breast04研究的亚组分析
errBREAST CANCER
IF2.9
err2024-06-17
err2
errOAAI
errYamashita, Toshinari; Sohn, Joo Hyuk; Tokunaga, Eriko; Niikura, Naoki; Park, Yeon Hee; Lee, Keun Seok; Chae, Yee Soo; Xu, Binghe; Wang, Xiaojia; Im, Seock-Ah; Li, Wei; Lu, Yen-Shen; Aguilar, Cecilia Orbegoso; Nishijima, Soichiro; Nishiyama, Yuji; Sugihara, Masahiro; Modi, Shanu; Tsurutani, Junji
err分享
err收藏
Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer
errCANCER RESEARCH
IF16.6
err2024-05-02
err0
PREAI
errFerraro, Emanuela; Khan, Atif; Plitas, George; Chen, Yuan; Ahmed, Mehnaj; An, Julia; Dang, Chau; Robson, Mark; Chandarlapaty, Sarat; Modi, Shanu; Razavi, Pedram; Shen, Sherry
err分享
err收藏
An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
errCANCER RESEARCH
IF16.6
err2024-05-02
err1
PREAI
errModi, Shanu; Salgado, Roberto; Guarneri, Valentina; Alagappan, Divi; Dennis, Natalie; Newell, Amy Hanlon; Boran, Aislyn; Morsli, Ouzna; Llombart-Cussac, Antonio
err分享
err收藏
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer靶向人类表皮生长因子受体2低乳腺癌的开放性问题，当前挑战和未来前景
errESMO OPEN
IF8.3
err2024-04-01
err5
errOAAI
errCurigliano, G.; Dent, R.; Earle, H.; Modi, S.; Tarantino, P.; Viale, G.; Tolaney, S. M.
err分享
err收藏
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)曲妥珠单抗deruxtecan在先前治疗的HER2-positive转移性乳腺癌患者中的应用: 一项II期临床试验 (DESTINY-Breast01) 的最新生存结果
errANNALS OF ONCOLOGY
IF65.4
err2024-03-01
err18
errOAAI
errSaura, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. -B.; Tamura, K.; Iwata, H.; Tsurutani, J.; Sohn, J.; Mathias, E.; Liu, Y.; Cathcart, J.; Singh, J.; Yamashita, T.
err分享
err收藏
First-in-Human Evaluation of Site-Specifically Labeled 89 Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
errJOURNAL OF NUCLEAR MEDICINE
IF9.1
err2024-01-25
err9
errOAAI
errYeh, Randy; O'Donoghue, Joseph A.; Jayaprakasam, Vetri Sudar; Mauguen, Audrey; Min, Ryan; Park, Sue; Brockway, Julia P.; Bromberg, Jacqueline F.; Zhi, W. Iris; Robson, Mark E.; Sanford, Rachel; Modi, Shanu; Agnew, Brian J.; Lyashchenko, Serge K.; Lewis, Jason S.; Ulaner, Gary A.; Zeglis, Brian M.
err分享
err收藏

研究方向

暂无研究方向
合作学者
合作期刊
M
Marc Ladanyi
H 指数: 204 · 论文数: 2.5K
W
William D. Travis
H 指数: 176 · 论文数: 1.1K
J
Jedd D. Wolchok
H 指数: 173 · 论文数: 1.4K
N
Nikolaus Schultz
H 指数: 162 · 论文数: 1.8K
V
Valerie W. Rusch
H 指数: 161 · 论文数: 1.1K
查看更多